API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
Ciraparantag is a novel small, water-soluble molecule being investigated for reversal of anticoagulation induced by direct oral anticoagulants (DOACs) or low molecular weight heparin (LMWH).
Lead Product(s): Ciraparantag
Therapeutic Area: Hematology Product Name: PER977
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Norgine
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 04, 2021
Details:
The published preclinical data demonstrate that ciraparantag has several key attributes including its ability to reverse the anticoagulant effect of apixaban, rivaroxaban, edoxaban, dabigatran, and LMWH.
Lead Product(s): Ciraparantag
Therapeutic Area: Hematology Product Name: PER977
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 19, 2020
Details:
Ciraparantag is in development for use in patients treated with direct oral anticoagulants and low molecular weight heparin when reversal of the anticoagulant effect of these products is needed for emergency surgery or due to life-threatening or uncontrolled bleeding.
Lead Product(s): Ciraparantag
Therapeutic Area: Hematology Product Name: PER977
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Norgine
Deal Size: $290.0 million Upfront Cash: $30.0 million
Deal Type: Licensing Agreement July 23, 2020
Details:
Results from both studies, which randomized a total of 113 subjects, showed that steady-state anticoagulation induced by apixaban or rivaroxaban was reversed by a single IV infusion of ciraparantag in a dose-related manner as assessed by whole blood clotting time (WBCT).
Lead Product(s): Ciraparantag
Therapeutic Area: Hematology Product Name: PER977
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 12, 2020